Edwin M. Posadas, MD | Authors

Articles

Dr. Posadas Discusses Darolutamide in Castration-Resistant Prostate Cancer

March 29, 2019

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.